Список проголосовавших за комментарий " Zimmer Biomet sees Q4 sales of approx $2.013 bln, Capital IQ consensus $1.971 bln; sees FY16 EPS at upper end of prior guidance (107.00)<ul><li>Expects fourth quarter net sales to be <strong>approximately $2.013 billion (Capital IQ consensus $1.971 bln), </strong>an increase of 4.1% over the prior year period. On an adjusted, constant currency basis, revenue increased by 4.4% over the prior year period, with the recently acquired LDR Holding Corporation contributing approximately 230 basis points. Previously, the Company had estimated fourth quarter revenue growth to be in a range of 1.0% to 2.0% on a similar basis.</li><li><strong>Preliminary full year net sales are projected to be $7.684 billion</strong>, an increase of 28.1% over the prior year.<ul><li>FY16 revenues increased by 2.3% on a constant currency, adjusted pro forma basis, excluding the contribution from the LDR transaction. Previously, the Company had estimated full year revenue growth to be in a range of 1.65% to 1.90% on a similar basis.</li></ul></li><li>The Company is <strong>unable to provide updated GAAP (reported) guidance </strong>for full-year 2016 diluted earnings per share, without unreasonable efforts, as the Company is finalizing the accounting for certain integration-related items that are excluded from the computation of adjusted diluted earnings per share. <strong>The Company now expects full year 2016 adjusted diluted earnings per share to be towards the upper end of the previously estimated range of $7.90 to $7.95.</strong></li></ul>"